Liraglutide Cost in Maryland 2026: Prices, Insurance, and Compounding Options

What Does Liraglutide Actually Cost in Maryland in 2026?

The price of liraglutide in Maryland varies by as much as $1,200 per month depending on your insurance status, pharmacy type, and whether you use a brand-name or compounded product. The Novo Nordisk manufacturer list price sits at $1,349 per month. Cash-pay patients at Maryland retail pharmacies pay closer to $900 per month on average, while patients who access liraglutide through a licensed 503A compounding pharmacy may pay as little as $150 per month.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally approved by the FDA as Victoza for type 2 diabetes in 2010 and later as Saxenda at a higher dose for chronic weight management in 2014 [1]. The drug works by mimicking the GLP-1 hormone to suppress appetite, slow gastric emptying, and improve insulin secretion. In the SCALE Obesity and Prediabetes trial (N=3,731), liraglutide 3.0 mg produced a mean weight loss of 8.0% at 56 weeks versus 2.6% with placebo (P<0.001) [2]. That clinical record is one reason Maryland prescribers write substantial volumes of liraglutide prescriptions each year.

The price gap between brand and compounded products is large enough to change treatment decisions. Understanding exactly which tier applies to your situation requires knowing your insurance plan, your diagnosis code, and your prescriber's familiarity with prior authorization processes.

Retail pricing across Maryland varies by pharmacy chain. A 30-day supply of Saxenda (liraglutide 3.0 mg, 5 pens) at a major Maryland chain pharmacy runs $870, $950 without insurance as of early 2026, consistent with data from the FDA drug pricing transparency tools [3]. Victoza pricing for diabetes indications runs slightly lower, averaging $820, $880 per month cash-pay at Maryland retail locations.

How Maryland Medicaid Covers Liraglutide

Maryland Medicaid covers liraglutide for both type 2 diabetes (Victoza) and chronic weight management (Saxenda), but both indications require prior authorization (PA). The PA criteria differ between indications.

For the diabetes indication, Maryland Medicaid (HealthChoice) typically requires documentation of inadequate glycemic control on metformin, a body mass index above 27 kg/m², and an HbA1c above 7.5% [4]. For the weight management indication, PA criteria align closely with FDA labeling: a body mass index of 30 kg/m² or higher, or a BMI of 27 kg/m² with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea [5].

Patients who meet these criteria and submit complete PA documentation are generally approved within 5, 10 business days through the Maryland Medicaid HealthChoice managed care organization (MCO) system. Denial rates for GLP-1 agents under Medicaid are a known barrier nationally. A 2023 analysis in JAMA Internal Medicine found that prior authorization denials for GLP-1 receptor agonists were overturned on appeal at rates exceeding 40% in several state Medicaid programs [6], which means an initial denial is worth contesting.

If you are enrolled in a Maryland Medicaid managed care plan such as CareFirst, UnitedHealthcare Community Plan Maryland, or Amerigroup Maryland, your plan's pharmacy benefit may have slightly different step-therapy requirements than the base HealthChoice formulary. Ask your prescriber to confirm the exact MCO formulary tier before submitting a PA.

The American Diabetes Association 2024 Standards of Care state: "In adults with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended" [7]. That guideline language is useful supporting documentation in a PA submission.

Compounded Liraglutide in Maryland: What Is and Is Not Legal

Compounded liraglutide is legal in Maryland when dispensed by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Maryland follows federal Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits compounding for individual patients when a commercially available product is not appropriate for that patient [8].

503A pharmacies compound for individual patients. 503B outsourcing facilities compound in larger batches for clinical use but are subject to stricter FDA oversight. In Maryland, 503A pharmacies may legally compound liraglutide because it is not on the FDA's list of drugs that may not be compounded due to being essentially a copy of an approved drug, provided the compounded formulation differs meaningfully from the commercially available product or the prescriber documents a clinical need [9].

The price difference is real. Compounded liraglutide from Maryland 503A pharmacies runs approximately $150 per month, compared to $900 at retail cash-pay prices. That is a difference of $750 per month, or $9,000 per year.

There are clinical caveats. Compounded products have not undergone the same FDA manufacturing review as brand-name liraglutide. Sterility, potency, and stability data vary by pharmacy. The FDA has issued warning letters to some compounders of GLP-1 peptides for quality concerns [10]. Patients choosing compounded liraglutide should verify their pharmacy holds a current Maryland Board of Pharmacy 503A license and uses a third-party analytical testing laboratory.

The Endocrine Society has noted that "compounded GLP-1 receptor agonists may not be therapeutically equivalent to FDA-approved products" and recommends patients discuss the risks and benefits with their prescriber before switching [11]. That guidance does not prohibit use; it places the decision in the patient-prescriber conversation.

503B outsourcing facilities are a separate category. They may ship to Maryland only when supplying office-use quantities to licensed practitioners. Direct-to-patient dispensing from a 503B facility without a 503A license is not permitted under Maryland or federal law [8].

Which Insurance Plans Cover Liraglutide in Maryland?

Maryland's commercial insurance market includes both employer-sponsored plans and individual marketplace plans sold through Maryland Health Connection. Coverage for liraglutide varies significantly by plan type and the diagnosis code on the prescription.

For the diabetes indication (Victoza, liraglutide 1.2 to 1.8 mg), most major commercial plans in Maryland cover liraglutide on Tier 2 or Tier 3 of the formulary. Blue Cross Blue Shield of Maryland, Cigna, and Aetna all list Victoza as a covered specialty medication with a typical member cost of $50, $150 per month after meeting the deductible, depending on plan design [12].

For the weight management indication (Saxenda, liraglutide 3.0 mg), coverage is more restrictive. Many employer-sponsored plans exclude anti-obesity medications entirely, a practice the American Heart Association has called "a barrier to evidence-based cardiovascular risk reduction" [13]. Patients with ACA marketplace plans in Maryland should check the Summary of Benefits and Coverage document for explicit anti-obesity medication language before assuming coverage.

Medicare Part D coverage for Saxenda remains excluded under current statute, as anti-obesity medications are not covered by Part D for weight loss as a primary indication. Victoza for diabetes is covered under Part D. This is a federal rule that applies in Maryland exactly as it applies nationwide [14].

State employees covered by the Maryland State Employee and Retiree Health and Welfare Benefits Program (SEHWBP) may have access to liraglutide through the State's CareFirst or UnitedHealthcare options, subject to the same PA processes described above. SEHWBP plan documents are updated annually; verify the current formulary at the Maryland Department of Budget and Management website.

The HealthRX Maryland GLP-1 Coverage Decision Framework below summarizes how a Maryland prescriber and patient should sequence their coverage investigation before choosing a payment pathway.

HealthRX Maryland GLP-1 Coverage Decision Pathway (2026)

1. Confirm diagnosis code: E11.x (type 2 diabetes) vs. E66.x (obesity). The code drives which drug and which formulary tier applies.
2. Check formulary tier: Request a formulary lookup from your plan's pharmacy benefit manager (PBM). Ask specifically about liraglutide and any required step-therapy drugs (metformin, bupropion-naltrexone).
3. Submit PA with clinical documentation: Include BMI, HbA1c, comorbidities, and documentation of prior therapy.
4. If denied: File a formal appeal. Attach the relevant guideline language from the ADA 2024 Standards [7] or the Endocrine Society obesity guidelines [15].
5. If still denied or uninsured: Evaluate the Novo Nordisk savings card (see below), GoodRx pricing at Maryland pharmacies, or a compounded option from a licensed 503A pharmacy.

Novo Nordisk Savings Programs and Discount Cards in Maryland

Novo Nordisk offers manufacturer savings cards for both Saxenda and Victoza. Eligible commercially insured patients may pay as little as $25 per month for Saxenda through the Saxenda My$avings Card program. The savings card does not apply to government-funded insurance (Medicaid, Medicare, TRICARE, or any federally funded plan), which excludes a substantial portion of Maryland's insured population [16].

For uninsured Maryland residents, the Novo Nordisk Patient Assistance Program (PAP) provides liraglutide at no cost to patients below 400% of the federal poverty level. In 2026, that threshold is approximately $60,240 per year for a single adult. Applications are submitted through NovoCare and typically require documentation of income, insurance status, and a valid prescription [16].

GoodRx and similar discount aggregators show cash-pay prices for liraglutide in Maryland ranging from $820 to $940 per month for Saxenda and $780 to $860 for Victoza, depending on the specific Maryland pharmacy. These prices are lower than the manufacturer list price but remain substantially higher than compounded alternatives.

Maryland does not operate a state-specific pharmaceutical assistance program that specifically covers liraglutide, as of January 2026. The Maryland Pharmacy Assistance Program (MPAP) covers certain medications for residents over age 65 or with disabilities, but GLP-1 agents are not currently on the MPAP formulary [17].

Telehealth Prescribing of Liraglutide in Maryland

Maryland permits telehealth prescribing of liraglutide without requiring an in-person visit, provided the prescribing clinician establishes a valid patient-provider relationship through a synchronous audio-video encounter [18]. Asynchronous (store-and-forward) prescribing of controlled substances is not permitted in Maryland, but liraglutide is not a controlled substance, so asynchronous consultations may be permissible depending on the telehealth platform's clinical protocols and Maryland Board of Physicians guidance.

The Maryland Board of Physicians updated its telehealth guidance in 2022 to align with post-pandemic flexibilities, allowing out-of-state practitioners to prescribe for Maryland patients provided they hold a Maryland medical license or a valid Interstate Medical Licensure Compact (IMLC) license [18]. Patients using national telehealth platforms should confirm their prescriber is licensed to practice in Maryland.

The practical result is that Maryland residents can receive a liraglutide prescription through a telehealth visit, have it filled at a Maryland retail pharmacy or shipped from a licensed 503A compounding pharmacy, and manage their medication without leaving home. The clinical follow-up cadence recommended for GLP-1 therapy includes monthly check-ins for dose titration during the first 5 weeks of therapy, then quarterly thereafter [15].

Liraglutide Dosing and the Clinical Case for Cost Investment

Understanding dosing helps contextualize the cost-per-outcome calculation. Liraglutide is titrated over 5 weeks: starting at 0.6 mg daily for one week, then 1.2 mg, 1.8 mg, 2.4 mg, and finally 3.0 mg for chronic weight management. Each weekly increase reduces gastrointestinal side effects during adaptation [1].

The SCALE Obesity trial published in the New England Journal of Medicine (N=3,731) showed that patients receiving liraglutide 3.0 mg lost a mean of 8.4 kg at 56 weeks, versus 2.8 kg with placebo (P<0.001) [2]. More than 63% of liraglutide-treated patients lost at least 5% of body weight, compared with 27% on placebo. Responders were defined as achieving at least 5% weight loss by week 16; non-responders were advised to discontinue therapy given low probability of subsequent benefit [2].

Cardiovascular outcomes data for liraglutide come primarily from the LEADER trial (N=9,340), which showed a 13% relative risk reduction in the primary composite cardiovascular endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) compared to placebo over a median follow-up of 3.8 years (HR 0.87; 95% CI 0.78, 0.97; P<0.001 for non-inferiority; P=0.01 for superiority) [19]. That cardiovascular benefit is the primary reason major guidelines recommend GLP-1 agents for patients with type 2 diabetes and high cardiovascular risk, and it is the basis on which many Maryland insurers approve PA requests.

Renal outcomes data also support liraglutide's value. In the LEADER trial, liraglutide reduced the composite renal outcome (new-onset macroalbuminuria, doubling of serum creatinine, end-stage renal disease, or renal death) by 22% versus placebo (HR 0.78; 95% CI 0.67, 0.92; P=0.003) [20]. For Maryland Medicaid patients with diabetic kidney disease, this datum can support a PA appeal on medical necessity grounds.

Comparing Liraglutide to Semaglutide in Maryland Pricing Context

Maryland prescribers and patients frequently compare liraglutide to semaglutide (Ozempic, Wegovy, Rybelsus) given that both are GLP-1 agonists. Semaglutide at 2.4 mg weekly (Wegovy) produced 14.9% mean weight loss at 68 weeks in the STEP-1 trial (N=1,961) versus 2.4% placebo (P<0.001) [21], a larger effect than liraglutide's 8% in SCALE. The trade-off is cost: Wegovy carries a list price of approximately $1,349, $1,650 per month in Maryland, comparable to or higher than Saxenda.

For patients whose insurance covers one but not the other, the formulary status matters more than the comparative efficacy difference. Some Maryland Blue Cross plans tier Ozempic (semaglutide for diabetes) more favorably than Saxenda, making semaglutide the lower out-of-pocket choice despite a higher list price [12]. A medication that a patient can actually afford and sustain for 12 months will produce better outcomes than a theoretically superior drug abandoned after two months.

Side Effects That Affect Adherence and Cost Calculations

Gastrointestinal side effects are the primary reason patients discontinue liraglutide. In SCALE, nausea occurred in 39.3% of liraglutide-treated patients versus 13.8% of placebo patients; vomiting in 15.7% versus 3.9% [2]. Most GI events are mild-to-moderate and peak during the first 4 weeks of dose titration.

The 5-week titration schedule exists specifically to reduce this discontinuation risk. Prescribers in Maryland telehealth settings should build titration monitoring into their follow-up protocols, as patients who stop liraglutide within the first 8 weeks due to side effects rather than lack of efficacy represent a preventable cost and outcome loss.

Rare but serious adverse effects include pancreatitis (incidence <0.5% in clinical trials) [2], gallbladder disease, and a theoretical thyroid C-cell tumor risk observed in rodent studies at suprapharmacologic doses. Liraglutide carries an FDA boxed warning for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 [1]. Maryland prescribers must document this contraindication check at initiation.

Practical Steps for Maryland Patients Starting Liraglutide in 2026

The fastest path to an affordable liraglutide prescription in Maryland in 2026 follows a specific sequence. First, schedule a telehealth visit with a Maryland-licensed prescriber. Second, confirm your diagnosis code before the visit, your BMI, HbA1c (if diabetic), and comorbidity list will determine which indication applies. Third, ask your prescriber to check your plan's formulary and submit a PA at the time of prescribing rather than waiting for a pharmacy rejection. Fourth, if your plan denies PA, file an appeal with ADA and Endocrine Society guideline citations. Fifth, if you are uninsured or the PA process stalls, request a 503A compounding pharmacy option or apply for the Novo Nordisk PAP.

A typical prior authorization for liraglutide in Maryland, when submitted with complete clinical documentation, is resolved within 5, 10 business days. Each week of delay represents approximately $30 in lost treatment time at the compounded price point, or $225 at retail cash-pay.